Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1/hTERT/Survivin DC Vaccine in AML with MRD
NCT05000801Phase 1Recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Jul 2021
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wt1 + htert + survivin + dendritic cell vaccine in acute myeloid leukemia (AML), sponsored by Academy of Military Medical Sciences. Primary endpoint: Incidence of Treatment Adverse Events. Started Jul 2021; status: recruiting.
02
Drugs
wt1 + htert + survivin + dendritic cell vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05000801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000801.